Charlotta Backman (M. Sc) has a strong background in clinical research, with over 15 years of experience in start-up, conduct and close-out of Phase I to Phase IV clinical trials, including trials in oncology and vaccines, but also in hypertension and dermatology. Charlotta joined Valo Therapeutics in March 2017, to oversee and lead all clinical operations and regulatory affairs.  Over the years, Charlotta has also gained experience from interactions with several regulatory authorities in the EU and in the US, both in terms of scientific advice and pre-IND meetings with the EMA and FDA, as well as through the clinical trial application processes in several countries. Charlotta worked in the CRO industry for Encorium and Remedium before taking on the responsibility and management of clinical trials in oncolytic virus immunotherapy at Oncos Therapeutics (later Targovax). Charlotta has a Master’s degree in Cell biology from Åbo Akademi University. During her academic career, Charlotta worked as a Researcher and Project Team Leader at the University of Helsinki and Folkhälsan Institute of Genetics in the field of disease genetics in rare genetically inherited disorders, before moving into clinical research.